HER2/neu Oncogene Silencing in a Breast Cancer Cell Model Using Cationic Lipid-Based Delivery Systems

Area of Science:

• Biotechnology
• Nanotechnology
• Oncology

Background:

• Overexpression of the human epidermal growth factor 2 (HER2/neu) oncogene is linked to poor breast cancer prognosis.
• Small interfering RNA (siRNA) offers a potential strategy for HER2/neu silencing.
• Effective delivery systems are crucial for siRNA-based cancer therapies.

Purpose of the Study:

• To evaluate cationic lipid-based systems for siRNA delivery targeting HER2/neu.
• To assess the safety, stability, and efficiency of these liposomal formulations.
• To compare the efficacy of novel lipoplexes with a commercial transfection agent.

Main Methods:

• Formulation of cationic liposomes using cholesteryl cytofectins (Chol-T or MS09) and dioleoylphosphatidylethanolamine (DOPE), with or without polyethylene glycol (PEG).
• Characterization of liposomes and siRNA lipoplexes for size, particle distribution, and nuclease protection.
• Assessment of siRNA transfection efficiency and HER2/neu gene silencing in HER2/neu-overexpressing SKBR-3 cells.

Main Results:

• Cationic liposomes effectively bound, compacted, and protected siRNA from degradation.
• Liposomes and lipoplexes were spherical, <200 nm, with PDI < 0.4.
• Non-PEGylated Chol-T-siRNA lipoplexes achieved significant HER2/neu mRNA (10,000-fold decrease) and protein (>111.6-fold decrease) silencing, outperforming Lipofectamine 3000.

Conclusions:

• Cationic liposomes are suitable and efficient carriers for HER2/neu siRNA delivery.
• These liposomal systems demonstrate potential for targeted gene silencing in breast cancer treatment.
• The developed lipoplexes offer a promising alternative to existing siRNA delivery methods.